<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923609</url>
  </required_header>
  <id_info>
    <org_study_id>CELLpEF</org_study_id>
    <nct_id>NCT02923609</nct_id>
  </id_info>
  <brief_title>Cell Therapy in HFpEF</brief_title>
  <acronym>CELLpEF</acronym>
  <official_title>A PILOT TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate safety and efficacy of transendocardial
      CD34+ cell therapy in patients with HFpEF by evaluating changes in myocardial structure and
      function, myocardial perfusion and electrical activity, biomarkers of neurohormonal
      activation, patient exercise capacity and clinical outcome.

      The secondary objective of the study is to better define the patophysiological background of
      HFpEF by the use of multimodality imaging platform, which will include data from
      electro-anatomical mapping, cardiac MRI, 2D and 3D echocardiography, high resolution
      electrocardiography, and cardiac catheterization
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in diastolic function (E/e') assessed by cMRI</measure>
    <time_frame>Baseline and 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity</measure>
    <time_frame>Baseline and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP levels</measure>
    <time_frame>Baseline and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>SC Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After enrollment, all patients will receive 5-day stem cell mobilization with G-CSF. Thereafter, patients will be randomly allocated to either active (SC Group) or control group (Controls) in a 2:1 ratio. Patients in the SC Group will undergo apheresis; CD34+ cells will be collected with immunomagnetic selection, and delivered transendocardialy in the target areas defined by electroanatomical mapping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the Control group, no apheresis or immunomagnetic selection of CD34+ cells will be performed; the patients will receive transendocardial injections of placebo using the same electroanatomical mapping protocol as in patients from the SC Group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell Therapy</intervention_name>
    <description>Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStarÂ® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.</description>
    <arm_group_label>SC Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control Procedure</intervention_name>
    <description>In the Control Group we will perform transendocardial injections using the same protocol as in the SC Group; stem cell suspension will be substituted with placebo (0.9% saline).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preserved left ventricular systolic function on echocardiography (LVEF&gt;50%)

          -  Evidence of diastolic dysfunction by echocardiography (E/e'&gt;15)

          -  Symptoms of heart failure (NYHA functional class II or III)

          -  NT-proBNP levels &gt;300 pg/ml

        Exclusion Criteria:

          -  Acute multi-organ failure

          -  History of any malignant disease within 5 years

          -  Diminished functional capacity due to non-cardiac co-morbidities (COPD, PAOD, morbid
             obesity)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bojan Vrtovec, MD, PhD</last_name>
    <phone>+3861 522 1157</phone>
    <email>bojan.vrtovec@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martina Jaklic, PhD</last_name>
    <phone>+3861 522 1148</phone>
    <email>martina.jaklic@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Vrtovec, MD, PhD</last_name>
      <phone>+3861 522 1157</phone>
      <email>bojan.vrtovec@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Martina Jaklic, PhD</last_name>
      <email>martina.jaklic@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Bojan Vrtovec, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Bojan Vrtovec</investigator_full_name>
    <investigator_title>Medical Director, Advanced Heart Failure and Transplantation Programme</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

